FDA Approved: DURYSTA — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Durysta (bimatoprost) submitted by Allergan, Inc. This marks approval of an add-on to the NDA for Durysta.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• DURYSTA (BIMATOPROST)

Snippet

SUPPL AP for DURYSTA (BIMATOPROST)